OUR MOTIVATION, MISSION AND VISION
We are Marie-Agnès (co-founder & CEO of Calico Biosystems), Riccardo Turrini (co-founder & CSO of Calico Biosystems) and Lucie Maillet (CBO).
Over the years of our career, we have witnessed the critical issue of the limited efficacy of anti-cancer drugs in patients with solid tumors, the huge attrition rate of drugs from the pre-clinical stage to approval for use in patients, and their high development costs. We launched Calico Biosystems to challenge this the status quo and provide cancer patient with life-saving drugs.
Calico Biosystems is built on the conviction that oncology will not advance through incremental improvements, but through a fundamental shift in how drugs are developed.
Calico Biosystems is a disruptive platform designed to integrate seamlessly into existing industry workflows, enabling rapid adoption. Built to scale, Calico Biosystems leverages strategic CRO partnerships and a growing proprietary patient data library that establishes a durable competitive moat.
Together, we accelerate the delivery of life‑changing treatments to patients with unprecedented speed and precision.
Our Team
Marie-Agnès Doucey
CEO & Co-founder
Engineer & PhD.
Former VP in IO drug development
Head of Industrial relations
15+ yrs as head of RnD and drug development programs in Oncology in public and private sectors, VP in Oncology
Riccardo Turrini
CSO & Co-founder
PhD in Oncology & Immunology
15+ yrs experience in deciphering hte immune response in tumor, program & team leader
Lucie Maillet St. Pierre
CBO
Former VP Customer Success Salesforce, Board Member B Leader
15+ years leading global transformation programs, strategic partnerships and high-performing teams across technology and life sciences; Chief Business Officer driving growth, strategic alliances and commercial expansion for biotech, pharma, CRO and AI innovators
OUR ADVISORY BOARD
Jean-Pierre Wery, Former CTO, JSR Lile Sciences, J; former Chairman Crown Biosciences, CN; CEO Mosaic Biosciences, USA
Ioannis Xenarios, Pr CHUV, CTO TwinEdge Bioscience, CH
Valérie Gateaux, Executive Finance Director, Sumitomo Pharma, CH
Laura Genatossio, Senior VP, General Manager EMEA, Avidity Biosciences, CH
OUR SCIENTIFIC BOARD
Michail Ignatiadis, Dr Jules Bordet Institute & EORTC Chairman, B
Mikaël Pittet, Pr HUG, Director Translational Oncology, CH
